Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 10 of 55 descriptions
| No. | 薬物名（臨床試験情報から抽出） | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | 指定難病告示番号 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bortezomib/dexamethasone (Maxidex) | 2件: Bortezomib Bortezomib,Dexamethasone (Maxidex) | 2件: Dexamethasone
Dexamethasone
(Maxidex),Bortezomib 💬 1. Bortezomib/dexamethasone
| 2件: NR3C1 NR3C1,PSMB5 💬 | 9件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 9件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-recepto ... | 1件: 283 283 💬1. Bortezomib/dexamethasone
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2 | Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone (Maxidex) Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone (Max ... | 2件: Bortezomib Bortezomib,Dexamethasone (Maxidex) | 2件: Dexamethasone
Dexamethasone
(Maxidex),Bortezomib 💬 2. Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
| 2件: NR3C1 NR3C1,PSMB5 💬 | 9件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 9件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-recepto ... | 1件: 28 28 💬2. Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3 | Bupivacaine/epinephrine/dexamethasone (Maxidex) | 3件: Bupivacaine Bupivacaine,Dexamethasone (Maxidex), Epinephrine | 3件: Epinephrine
Epinephrine
,Dexamethasone (Maxidex), Bupivacaine 💬 3. Bupivacaine/epinephrine/dexamethasone
| 15件: ADRA1A ADRA1A,ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, NR3C1, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 15件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, NR3C1, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A ... 3. Bupivacaine/epinephrine/dexamethasone
| 16件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 16件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chem ... | 1件: 96 96 💬3. Bupivacaine/epinephrine/dexamethasone
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 4 | Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine (Maxidex) | 3件: Azathioprine Azathioprine,Dexamethasone (Maxidex), Rituximab | 3件: Azathioprine
Azathioprine
,Dexamethasone (Maxidex), Rituximab 💬 4. Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine
| 2件: MS4A1 MS4A1,NR3C1 💬 | 2件: Hematopoietic cell lineage Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬 | 1件: 35 35 💬4. Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 5 | Control intervention (no dexamethasone) (Maxidex) | 1件: Dexamethasone Dexamethasone (Maxidex) | 1件: Dexamethasone
Dexamethasone
(Maxidex) 💬5. Control intervention (no dexamethasone)
| 1件: NR3C1 NR3C1 💬5. Control intervention (no dexamethasone)
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬5. Control intervention (no dexamethasone)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 6 | Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone) (Maxidex) Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, predn ... | 7件: Acetate Acetate,Cortisone, Cortisone acetate, Dexamethasone (Maxidex), Hydrocortisone, Prednisolone, Prednisone 7件: Acetate, Cortisone, Cortisone acetate, Dexamethasone(Maxidex), Hydrocortisone, Prednisolone, Prednison ... | 6件: Hydrocortisone
Hydrocortisone
,Dexamethasone (Maxidex), Prednisolone , Prednisone , Cortisone acetate , Cortisone 💬 6件: Hydrocortisone , Dexamethasone (Maxidex), Prednisolone , Prednisone , Cortisone acetat ... 6. Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)
| 1件: NR3C1 NR3C1 💬6. Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬6. Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 7 | Cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen (Maxidex) | 3件: Bortezomib Bortezomib,Cyclophosphamide, Dexamethasone (Maxidex) | 4件: Cyclophosphamide
Cyclophosphamide
,Dexamethasone (Maxidex), Bortezomib , Cyclophosphamide 💬 7. Cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
| 2件: NR3C1 NR3C1,PSMB5 💬 | 9件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 9件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-recepto ... | 1件: 28 28 💬7. Cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 8 | Cyclophosphamide, Bortezomib, dexamethasone (Maxidex) | 3件: Bortezomib Bortezomib,Cyclophosphamide, Dexamethasone (Maxidex) | 4件: Cyclophosphamide
Cyclophosphamide
,Dexamethasone (Maxidex), Bortezomib , Cyclophosphamide 💬 8. Cyclophosphamide, Bortezomib, dexamethasone
| 2件: NR3C1 NR3C1,PSMB5 💬 | 9件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 9件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-recepto ... | 1件: 28 28 💬8. Cyclophosphamide, Bortezomib, dexamethasone
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 9 | Cyclophosphamide, Bortezomib, dexamethasone plus Daratumumab (Maxidex) | 4件: Bortezomib Bortezomib,Cyclophosphamide, Daratumumab, Dexamethasone (Maxidex) | 5件: Cyclophosphamide
Cyclophosphamide
,Dexamethasone (Maxidex), Bortezomib , Cyclophosphamide , Daratumumab 💬 5件: Cyclophosphamide , Dexamethasone (Maxidex), Bortezomib , Cyclophosphamide , Daratumuma ... 9. Cyclophosphamide, Bortezomib, dexamethasone plus Daratumumab
| 3件: CD38 CD38,NR3C1, PSMB5 💬 | 16件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Calcium signaling pathway, Hematopoietic cell lineage, Huntington disease, Metabolic pathways, Neuroactive ligand-receptor interaction, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Salivary secretion, Spinocerebellar ataxia 💬 16件: Alzheimer disease, Amyotrophic lateral sclerosis, Calcium signaling pathway, Hematopoietic cell ... | 1件: 28 28 💬9. Cyclophosphamide, Bortezomib, dexamethasone plus Daratumumab
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 10 | Dexamethasone (Maxidex) | 1件: Dexamethasone Dexamethasone (Maxidex) | 1件: Dexamethasone
Dexamethasone
(Maxidex) 💬10. Dexamethasone
| 1件: NR3C1 NR3C1 💬10. Dexamethasone
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 22件: 13 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 81, 84, 96, 97, 162, 222, 235, 257, 283, 296, 299 💬 22件: 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 81, 84, 96, 97, 162, 222, 235, 257, 283, 296, 299💬 ... 10. Dexamethasone
|